Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.540
+0.010 (0.65%)
At close: Mar 13, 2026, 4:00 PM EDT
1.500
-0.040 (-2.58%)
After-hours: Mar 13, 2026, 7:50 PM EDT
Pyxis Oncology Revenue
Pyxis Oncology had revenue of $2.82M in the twelve months ending September 30, 2025, down -82.53% year-over-year. In the year 2024, Pyxis Oncology had annual revenue of $16.15M.
Revenue (ttm)
$2.82M
Revenue Growth
-82.53%
P/S Ratio
34.00
Revenue / Employee
$64,091
Employees
44
Market Cap
95.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.15M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 62.30M |
| Q32 Bio | 53.74M |
| Verrica Pharmaceuticals | 35.58M |
| Seer, Inc. | 16.58M |
| aTyr Pharma | 190.00K |
PYXS News
- 5 weeks ago - Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity - GlobeNewsWire
- 3 months ago - Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
- 3 months ago - Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript - Seeking Alpha
- 3 months ago - Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewsWire
- 4 months ago - Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings - GlobeNewsWire
- 5 months ago - Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - GlobeNewsWire